VIR sentiment intelligence

Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 12:30

Source

Market source

Vir Biotechnology, Inc. $VIR Shares Bought by Candriam S.C.A.

Candriam S.C.A. increased its stake in Vir Biotechnology (NASDAQ:VIR) by 10.1% in the first quarter, holding over 1.1 million shares valued at approximately $10.2 million. Other institutional investors also adjusted their positions, resulting in 65.32% institutional ownership. Wh

Tone

Neutral 50/100

Event

Earnings

Published

13 Jul 2026 08:40

Source

MarketBeat

If You Invested $1,000 in Vir Biotechnology, Inc. (VIR)

This article analyzes the historical stock performance of Vir Biotechnology, Inc. (VIR). It calculates the returns on hypothetical $1,000 investments made one and five years ago, showing disparate outcomes. The article also provides an overview of Vir Biotechnology's focus on inf

Tone

Neutral 50/100

Event

Market update

Published

04 Jul 2026 09:09

Source

Stock Titan

Vir Biotechnology, Inc. $VIR Stock Holdings Increased by Pictet Asset Management Holding SA

Pictet Asset Management Holding SA significantly increased its stake in Vir Biotechnology (NASDAQ:VIR) by 10,878.9% in Q1, now owning 1.48 million shares worth $13.3 million. This increase comes despite Vir Biotechnology reporting weaker than expected quarterly results and analys

Tone

Neutral 50/100

Event

Earnings

Published

03 Jul 2026 09:11

Source

MarketBeat

VIR - Vir Biotechnology Inc Latest SEC Filings

This page provides an overview of Vir Biotechnology Inc (VIR) focusing on its latest SEC filings and comprehensive financial data. It includes key stock performance metrics, valuation ratios, and insider/institutional ownership percentages, alongside recent earnings figures and a

Tone

Neutral 50/100

Event

Earnings

Published

02 Jul 2026 11:11

Source

Finviz

Form 144 Vir Biotechnology For: 29 June By Investing.com

This article from Investing.com reports on a Form 144 filing by Vir Biotechnology for June 29. It includes the stock symbol VIR and its performance on that date, amidst various market data and other news. The content primarily serves as a placeholder for the filing information, a

Tone

Neutral 50/100

Event

Market update

Published

30 Jun 2026 19:39

Source

Investing.com Nigeria

OP Asset Management Ltd Takes Position in Vir Biotechnology, Inc. $VIR

OP Asset Management Ltd has acquired a new position in Vir Biotechnology, purchasing 113,028 shares valued at approximately $1.013 million in the first quarter of 2026. This move comes as institutional investors now own 65.32% of the company's shares. Despite a recent weak quarte

Tone

Neutral 50/100

Event

Earnings

Published

30 Jun 2026 09:09

Source

MarketBeat

[144] Vir Biotechnology, Inc. SEC Filing

This article reports on Vir Biotechnology, Inc.'s SEC Form 144 filing, which indicates a proposed sale of securities. The filing details include the sale of 16,000 shares of common stock acquired through a stock option exercise, with an aggregate market value of $165,138.95, and

Tone

Neutral 50/100

Event

Market update

Published

29 Jun 2026 21:40

Source

Stock Titan

Price to sales forward of Vir Biotechnology, Inc. – NASDAQ:VIR

This article provides financial information for Vir Biotechnology, Inc. (NASDAQ: VIR), specifically focusing on its forward price-to-sales ratio. It appears to be a financial data point or a report generated by TradingView, detailing a specific period's value, change, and percent

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 17:39

Source

TradingView

Enterprise value to EBIT forward of Vir Biotechnology, Inc. – NASDAQ:VIR

This article focuses on the enterprise value to EBIT forward metric for Vir Biotechnology, Inc. (NASDAQ: VIR). It directly presents the financial data for this specific metric without further analysis or commentary within the provided content. The details are presented in a strai

Tone

Neutral 50/100

Event

Market update

Published

26 Jun 2026 11:09

Source

TradingView

VIR: Hepatitis Delta Program And Oncology Partnership Will Drive Future Upside

Analysts have increased their average price target for Vir Biotechnology to $21.56, up from $20.67, driven by an improved revenue growth outlook and a higher future P/E assumption, factoring in the potential of emerging hepatitis delta virus therapies. The company is advancing in

Tone

Neutral 50/100

Event

Earnings

Published

23 Jun 2026 17:09

Source

Simply Wall Street

Vir Biotechnology Inc (VIR) Risk Assessment: Volatility, Financial Risk & Investment Risk

Vir Biotechnology Inc (VIR) has a current risk assessment score of 4.70, placing it 67th out of 389 in the Biotechnology & Medical Research industry. The company's beta of 1.66 indicates higher volatility compared to the S&P 500. The report details various risk metrics including

Tone

Neutral 50/100

Event

Market update

Published

23 Jun 2026 08:40

Source

TradingKey

Vir Biotechnology, Inc. (NASDAQ:VIR) Given Average Recommendation of "Moderate Buy" by Brokerages

Vir Biotechnology, Inc. (NASDAQ:VIR) has received a consensus "Moderate Buy" rating from nine brokerages, with an average 1-year price target of $20.88. Recent analyst updates were largely positive, including increased price targets from several firms, though Weiss Ratings mainta

Tone

Neutral 50/100

Event

Analyst action

Published

22 Jun 2026 06:39

Source

MarketBeat

Vir Biotechnology (VIR) Stock Could Be 56% Undervalued After New PSMA Data

Tone

Neutral 50/100

Event

Market update

Published

21 Jun 2026 07:00

Source

simplywall.st

Is Vir Biotechnology (VIR) Quietly Recasting Its Governance Strength With a New Audit Committee Chair?

Tone

Neutral 50/100

Event

Market update

Published

18 Jun 2026 07:00

Source

simplywall.st

Vir Biotechnology Inc (VIR) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article from TradingKey provides a revenue breakdown for Vir Biotechnology Inc (VIR), noting that relevant data for business segments, regional revenue, and profit contribution for FY2025 has not yet been disclosed by the company. It indicates that the United States contribu

Tone

Neutral 50/100

Event

Earnings

Published

17 Jun 2026 05:11

Source

TradingKey

Vir Biotechnology (VIR) director awarded RSUs and stock options in new grants

Vir Biotechnology director Timothy Coughlin has been granted restricted stock units (RSUs) and stock options. He received two RSU awards of 8,000 shares each and two stock option grants covering 16,000 shares each, with an exercise price of $8.51 per share, expiring in 2036. Thes

Tone

Neutral 50/100

Event

Market update

Published

12 Jun 2026 17:09

Source

Stock Titan

Vir Biotechnology (VIR) director Coughlin reports zero share ownership

Vir Biotechnology director Timothy Coughlin filed an initial Form 3, reporting zero beneficial ownership of the company's common stock as of June 9, 2026. This SEC filing establishes his initial position as an insider, showing no direct holdings. A Form 3 is required when an indi

Tone

Neutral 50/100

Event

Market update

Published

11 Jun 2026 22:40

Source

Stock Titan

Morgan Stanley Raises Vir Biotechnology (NASDAQ:VIR) Price Target to $27.00

Morgan Stanley has increased its price target for Vir Biotechnology (NASDAQ:VIR) to $27.00 from $23.00, maintaining an "overweight" rating. This adjustment suggests a potential upside of 227.27% from the current stock price. Despite weak recent earnings, insider selling, and mixe

Tone

Neutral 50/100

Event

Analyst action

Published

11 Jun 2026 13:09

Source

MarketBeat

Vir Biotechnology appoints Timothy Coughlin to board

Vir Biotechnology (NASDAQ:VIR) has announced the appointment of Timothy Coughlin to its board of directors and as chair of the audit committee, effective June 9, 2026. Coughlin brings extensive financial and biotechnology experience, having previously served as CFO of Neurocrine

Tone

Neutral 50/100

Event

Market update

Published

11 Jun 2026 11:09

Source

Investing.com

Puma Biotechnology Stock Rises 19% in 3 Months: Here's Why

Tone

Neutral 50/100

Event

Market update

Published

11 Jun 2026 07:00

Source

TradingView

[8-K] Vir Biotechnology, Inc. Reports Material Event

Vir Biotechnology, Inc. has announced the appointment of Timothy Coughlin, CPA, to its Board of Directors, increasing the board size from seven to eight members. Coughlin will serve as a Class III director until the 2028 annual meeting and has also been appointed Chair of the Aud

Tone

Neutral 50/100

Event

Market update

Published

10 Jun 2026 20:39

Source

Stock Titan

WINTON GROUP Ltd Buys 131,555 Shares of Vir Biotechnology, Inc. $VIR

WINTON GROUP Ltd significantly increased its stake in Vir Biotechnology, Inc. (NASDAQ:VIR) by purchasing an additional 131,555 shares, bringing its total holding to 189,306 shares valued at approximately $1.14 million. This increased ownership comes despite Vir Biotechnology repo

Tone

Neutral 50/100

Event

Deals and strategy

Published

10 Jun 2026 11:39

Source

MarketBeat